Nearly 80% of U.S. neurologists prescribing drugs for multiple sclerosis (MS) have received at least one pharma industry payment, with higher-volume prescribers more likely to be beneficiaries, finds a five-year analysis of Medicare database payments, published in the journal BMJ Open.
This article was originally published on MedicalXpress.com